Journal Article

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

Chesson, Brent, Lau, Eddie, Reynolds, Hayley M., Siva, Shankar, Montgomery, Rebecca, Brook, Nicholas R., De Abreu Lourenco, Richard, Kron, Tomas, Ruben, Jeremy, Khoo, Vincent, Sridharan, Swetha, Bressel, Mathias, Higgs, Braden, Lawrentschuk, Nathan, Hardcastle, Nicholas, Martin, Jarad, Hofman, Michael S., Foroudi, Farshad, Pryor, David, Vanneste, Ben

2018

Overview

Background Stereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control primary renal cell cancer (RCC) in patients that are medically inoperable or at high-risk of post-surgical dialysis. The objective of the FASTRACK II clinical trial is to investigate the efficacy of SABR for primary RCC. Methods FASTRACK II is a single arm, multi-institutional phase II study. Seventy patients will be recruited over 3 years and followed for a total of 5 years. Eligible patients must have a biopsy confirmed diagnosis of primary RCC with a single lesion within a kidney, have ECOG performance ≤2 and be medically inoperable, high risk or decline surgery. Radiotherapy treatment planning is undertaken using four dimensional CT scanning to incorporate the impact of respiratory motion. Treatment must be delivered using a conformal or intensity modulated technique including IMRT, VMAT, Cyberknife or Tomotherapy. The trial includes two alternate fractionation schedules based on tumour size: for tumours ≤4 cm in maximum diameter a single fraction of 26Gy is delivered; and for tumours > 4 cm in maximum diameter 42Gy in three fractions is delivered. The primary outcome of the study is to estimate the efficacy of SABR for primary RCC. Secondary objectives include estimating tolerability, characterising overall survival and cancer specific survival, estimating the distant failure rate, describing toxicity and renal function changes after SABR, and assessment of cost-effectiveness of SABR compared with current therapies. Discussion The present study design allows for multicentre prospective validation of the efficacy of SABR for primary RCC that has been observed from prior single institutional and retrospective series. The study also allows assessment of treatment related toxicity, overall survival, cancer specific survival, freedom from distant failure and renal function post therapy. Trial registration Clinicaltrials.gov NCT02613819 , registered Nov 25th 2015.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adrenal / Adult / Biomedical and Life Sciences / Biomedicine / Biopsy / Cancer / Cancer Research / Cancer therapies / Carcinoma, Renal Cell - mortality / Carcinoma, Renal Cell - physiopathology / Carcinoma, Renal Cell - radiotherapy / Care and treatment / Clinical trials / Consortia / Cryotherapy / Dialysis / Health Promotion and Disease Prevention / Humans / Kidney / Kidney cancer / Kidney Neoplasms - mortality / Kidney Neoplasms - physiopathology / Kidney Neoplasms - radiotherapy / Kidneys / Medical and radiation oncology / Medical imaging / Medicine/Public Health / Metastases / Metastasis / Methods / Multicenter Studies as Topic / Oncology / Patients / Radiation therapy / Radiosurgery / Radiosurgery - adverse effects / RCC / Renal cell carcinoma / Renal failure / Renal function / SABR / SBRT / Study Protocol / Surgery / Surgical Oncology / Toxicity / Treatment Outcome / Tumors